- Home
- DAVEW vs BRTX Comparison
DAVEW vs BRTX Comparison
Compare DAVEW & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVEW | BRTX |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | 280 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 4.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DAVEW | BRTX |
|---|---|---|
| Price | $0.48 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.0K | ★ 6.5M |
| Earning Date | 03-06-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.08 |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $319,355,000.00 | $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | $0.14 | ★ N/A |
| Revenue Growth | ★ 30.00 | N/A |
| 52 Week Low | $0.12 | $0.19 |
| 52 Week High | $2.73 | $2.10 |
Technical Indicators
Market Signals| Indicator | DAVEW | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 44.53 |
| Support Level | $0.26 | $0.19 |
| Resistance Level | $0.67 | $1.18 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 27.10 | 99.18 |
Price Performance
Historical ComparisonAbout DAVEW Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit, short-term liquidity, fee-free banking, and financial management tools, and finding side gigs.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.